Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...

CVRx, Inc. announced recently that the Centers for Medicare and Medicaid Services (CMS) assigned the company’s Barostim p ...

A nationwide retrospective study evaluated health care resource utilization and outcomes among patients with ...

Two-year outcomes were reported from the CLOUT registry, which is a prospective, multicenter study evaluating patient ...

A study assessed the effects of intravascular volume expansion on deep pelvic vein size using the 200-150-125 rule for the ...

The 24-month outcomes from the VIVID clinical trial, which evaluated the safety and efficacy of the Duo venous stent system ...

Secondary outcomes through 6 months were reported from the VenaSeal Spectrum Surgical Stripping study, a randomized ...

In the LIFE-BTK trial, several initiatives were implemented to facilitate enrollment of diverse populations, ensuring that pati ...

The Disrupt PAD BTK II study’s 30-day outcomes were revealed. The core lab–adjudicated, prospective, multicenter, s ...

Royal Philips announced enrollment of the first patient in THOR, a United States investigational device exemption (IDE) clinica ...

DEEPER OUS is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland ...

The safety and effectiveness of the Neuroguard IEP (Contego Medical)—a three-in-one carotid stent system with integrated ...